Master Investor – Investing in the Age of Longevity



We are on the verge of a lifespan revolution. In the next 30 years, life expectancy is going to rise to between 110 and 120.

The nascent but rapidly growing longevity industry has the capacity to change forever how we live, and how (and when) we die. Crucially, it will also influence how we successfully invest for the future.

How can we as investors and advisors prosper in this new era of longevity?

Our one-day masterclass, Investing in the Age of Longevity, offers you the rare chance to be involved (and invested) in the birth of a new industry – arguably the greatest investment opportunity of all time.

A packed programme of presentations – all delivered by scientists and business leaders at the cutting edge of the field – ensures you’ll leave the event with valuable learning points to help build your longevity investment portfolio.

Spaces are limited  to 150 attendees so we advise to book early.

Date: 17 November 2021 | 9am-5pm
Location: London


Jim Mellon

Host speaker
Jim is an entrepreneur with a flair for identifying emerging global trends enabling him to build a worldwide business empire. He is amongst the top 10% in the “Sunday Times Rich List” (Britain’s equivalent to the Forbes list). He is often described as the British Warren Buffett and he predicted the Credit Crunch of 2007-08 in a book entitled “Wake Up! Survive and Prosper in the Coming Economic Turmoil”. Jim followed this with “The Top 10 Investments for the Next 10 Years” (2008) and subsequently “Cracking the Code” (2012), “Fast Forward” (2014) and, most recently, “Juvenescence” (2017). His monthly “Mellon on the Markets” column in Master Investor Magazine has gained him cult status among investors. He holds a master’s degree in Politics, Philosophy and Economics from Oxford University. He is on the Board of Trustees of the Buck Institute in California, a trustee of the Biogerontology Institute, and a Fellow of Oriel College, Oxford.

Phil Newman

First Longevity
Phil Newman is Editor in Chief of www.Longevity.Technology, the key daily news platform for Longevity investment, research and new business.
As an international consultant for over 25 years Phil has delivered C-level management, marketing and business development expertise to start-ups, scale-ups and enterprises.
Market experience includes: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability. He is the founder of First Longevity which operates 2 digital businesses in the field of Longevity, including Crowd Longevity: the digital platform for equity funding Longevity start-ups and scale-ups.

Greg Bailey

Greg Bailey, a physician and financier, is co-founder and CEO of Juvenescence. The company aims to solve the problem of human aging by investing in technologies and treatments that are most likely to extend human lifespans and deliver high returns to shareholders.
Greg is a serial entrepreneur in biotech and also serves as chairman of Portage Biotech, a publicly-traded oncology drug development company. Previously, he has been managing partner at Palantir Group, director at Medivation, and board member at Biohaven Pharmaceuticals Holding Company.

Nir Barzilai MD

Director of the Institute for Aging Research at the Albert Einstein College of Medicine
Dr. Barzilai is a chaired Professor of Medicine and Genetics and Director of the biggest Center in the world to study the Biology of Aging. He is the recipient of an NIH Merit Award aiming to extend the healthy life span in rodents by biological interventions. He also studies families of centenarians that have provided genetic/biological insights on the protection against aging. Several drugs are developed based, in part, on these paradigm-changing studies. He is a recipient of numerous prestigious awards, including the recipient of the 2010 Irving S. Wright Award of Distinction in Aging Research and is the 2018 recipient of the IPSEN Longevity award.

He is leading the TAME (Targeting/Taming Aging with Metformin) multi central study to prove that concept that multi morbidities of aging can be delayed in humans and change the FDA indications to allow for next generation interventions. He is a founder of CohBar Inc. (now public company) and Medical Advisor for Life Biosciences. He is on the board of AFAR and CohBar He has been featured in major papers, TV program and documentaries (TEDx and TEDMED) and has been consulting or presented the promise for targeting aging at The Singapore Prime Minister Office, several International Banks, The Vatican, Pepsico, Milkin Institute, The Economist and Wired Magazine.

Albert Einstein College of Medicine
Albert Einstein College of Medicine is a research-intensive medical school. For more than 60 years, our diverse faculty and staff have set the standard for excellence in medical and graduate education and patient-centered clinical care, and have made major contributions to scientific research enhancing human health in our communities and beyond. Our mission is to prepare a diverse body of students to become knowledgeable, compassionate physicians and innovative scientific investigators, and to create new knowledge.

Richard Faragher

University of Brighton
Richard Faragher is Professor of Biological Gerontology at the University of Brighton and is past Chair of the British Society for Research on Ageing, the International Association of Biomedical Gerontology and the American Aging Association. He read Biochemistry at Imperial College, London and undertook doctoral studies on human premature ageing at the University of Sussex. His primary research interest is the relationship between cellular senescence and organismal ageing.

He holds the Royal Pharmaceutical Society Conference Science Medal for his work on the mechanisms of Werner’s syndrome, the Help the Aged ‘Living Legend’ award for his championship of older people, the Paul F Glenn Award for research into the mechanisms of ageing and the British Society for Research on Ageing’s highest honour, the Lord Cohen of Birkenhead Medal. He is a Fellow of the American Aging Association and serves on the Editorial Boards of Advances in Biogerontology, Mechanisms of Aging and Development and Biogerontology.

Professor Faragher has served as a member of the Research Advisory Council of the Charity Research into Ageing and on strategy and funding panels for the BBSRC, the US National Institutes on Ageing and the European Union. From 2005-2008 he was Co-director of the BBSRC-EPSRC SPARC programme, a research network designed to build national capacity to conduct inter-disciplinary ageing research. He is currently a Director of the American Federation for Aging Research, the leading US non-profit organization supporting and advancing healthy aging through biomedical research and serves on the Scientific Advisory Board of the Longevity Vision Fund an investment fund dedicated to making longevity affordable and accessible to all.

Stephanie Lederman, Ed.M.

Executive Director, AFAR
Stephanie Lederman is executive director of the American Federation for Aging Research (AFAR), a leading, not-for-profit organization supporting biomedical research on aging. Under Ms. Lederman’s leadership for over 25 years, AFAR has grown into an organization that has been able to contribute more than $189 million to nearly 4,300 new investigators and students conducting biomedical research on aging processes and age-related diseases.

She serves as the Co-Principal Investigator for the Nathan Shock Centers of Excellence in the Basic Biology of Aging Coordinating Center and the Research Centers Collaborative Network (RCCN) and is the Co-Investigator for the National Program Office Clin-STAR (Clinician-Scientists Transdisciplinary Aging Research) initiative—three programs of the National Institute on Aging (NIA) of the U.S. National Institutes of Health (NIH).

An advocate for aging research, she works promote the field through raising funds for the research pipeline, organizing scientific meetings, and leading outreach to the general public and media.

During the course of her career in the not-for-profit sector, Ms. Lederman has served as executive director of The National Center for Health Education and has held leadership positions at The American Red Cross in Greater New York, Memorial Sloan-Kettering Cancer Center, and The American Heart Association. She holds a master’s degree from Boston University.

She is a Fellow of the New York Academy of Medicine, a member of the Board of Directors of the American Aging Association, a member of Royal Society of Medicine, and a member of the New York Academy of Sciences.

James L. Kirkland, MD, PhD

AFAR President
James L. Kirkland,MD, PhD is the Director of the Robert and Arlene Kogod Center on Aging at Mayo Clinic and Noaber Foundation Professor of Aging Research. Dr. Kirkland’s research focuses on
cellular senescence, age-related adipose tissue and metabolic dysfunction, and development of agents and strategies for targeting fundamental aging mechanisms to treat age-related chronic diseases and disabilities and to extend healthspan. He published the first article about drugs that clear senescent cells /
senolytic agents.

A novel, mechanism-based, hypothesis-driven drug development paradigm was used to discover senolytic drugs. Based on the observation that senescent cells release factors that cause apoptosis of the cells around them, yet are themselves resistant to apoptosis, Dr. Kirkland hypothesized that senescent cells utilize senescent cell anti-apoptotic pathways (SCAPs) for protection from their own senescence-associated secretory phenotype (SASP). Using bioinformatics analyses of senescent vs. non-senescent cells and RNA interference, Dr. Kirkland identified these SCAPs and verified their importance for senescent cell survival. Dr. Kirkland used bioinformatics approaches to identify agents that target key nodes across the SCAP network and demonstrated these drugs are senolytic in rodent and human cultured cells and mice in vivo, These senolytic drugs include Dasatinib (D), Quercetin (Q), Fisetin, Navitoclax, and related compounds.

Dr. Kirkland showed these agents delay, prevent, or alleviate multiple disorders in mouse models of human chronic diseases and aging phenotypes. Conditions alleviated in mouse models include frailty, diabetes, hepatic steatosis, cirrhosis, renal dysfunction, neuropsychiatric disorders, dementias, pulmonary fibrosis, osteoporosis, osteoarthritis, retinal degeneration, diastolic dysfunction, cardiac ischemia, vascular hyporeactivity, infertility, and skin disorders, among others. He demonstrated that intermittent, orally administered senolytics reduce senescent cell abundance in adipose tissue and blood markers of senescent cell burden in blood of patients with diabetic kidney disease. He and collaborators found that a brief course of senolytics enhances physical function and reduces frailty in patients with idiopathic pulmonary fibrosis, a fatal, cellular-senescence-driven disease for which available treatments have been unsatisfactory. Multiple clinical trials are currently underway of the senolytics that Dr. Kirkland discovered.

He is a scientific advisory board member for several companies and academic organizations. In addition to being President of AFAR, he has been a member of the National Advisory Council on Aging of the National Institutes of Health, and past chair of the Biological Sciences Section of the Gerontological Society of America. He holds honorary appointments at Boston University and the University of Groningen in the Netherlands. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism.

Janet Lord, FMedSci

Director, Institute for Inflammation and Ageing at the University of Birmingham
Janet Lord is Professor of Immune Cell Biology and Director of the Institute for Inflammation and Ageing at the University of Birmingham. She is also Director of the MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research and theme lead for sarcopaenia in the NIHR Birmingham Biomedical Re-search Centre and leads the acute response to injury themes in the NIHR Surgical Reconstruction and Microbiology Research Centre and the Scar Free Foundation Centre for Burns Research.

Her primary research focus is on the effect of ageing upon immune function and how this limits the ability of older adults to resolve inflammation occurring in response to infectious challenge or injury. This has led her to research neutrophil function in healthy elders and also after hip fracture and during infections such as pneumonia. She also researches the link between chronic systemic inflammation and physical frailty in old age and has published papers showing that much of the increased systemic inflammation and sarcopaenia associated with ageing can be prevented by high levels of physical activity in adulthood.
Professor Lord has a particular interest in the role played by stress (physical and psychological) and the altered HPA axis in modulating immunity and frailty in old age and following an injury such as hip fracture.

She has published several papers showing that a heightened HPA axis (increased corti-sol:DHEAS ratio) is associated with poor outcomes after hip fracture.

In 2013 she was awarded the Lord Cohen of Birkenhead medal for her outstanding research in human ageing by the British Society for Research in to Ageing. She was elected a Fellow of the Academy of Medical Sciences in 2015. She has published over 200 original papers and reviews.


Schedule Overview

Date Number of Sessions First Session Starts Last Session Ends
Wednesday 17th 2021 1 09:00 AM 05:00 PM

Schedule Details

Day Time Session Details
Day 1 09:00 AM05:00 PM


Ticket Price
Early Bird Ticket £100
General Ticket £300

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…